Ablation Targets of Scar-related Ventricular Tachycardia Identified by Dynamic Functional Substrate Mapping

Ain Shams University40 enrolled

Overview

This study aims at comparing the recurrence rates of ventricular tachycardia ablated after being mapped by 2 different techniques.

The study participants are patients presented with recurrent ventricular tachycardia. They will be divided into 2 groups in terms of mapping. The first group will use mapping during sinus rhythm to identify late potentials that may be incriminated in the tachycardia circuit. The other group will undergo mapping during right ventricular extrastimulus pacing to unmask hidden potentials. The identified potentials will be ablated in both groups.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Tachycardia, Ventricular

Interventions

Radiofrequency ablationPROCEDURE

Both groups will undergo radiofrequency ablation of potentials likely responsible for the tachycardia. Those potentials are identified by the formentioned 2 distinct methods.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * • Patients with structural heart disease; previous myocardial infarction, left ventricular dilatation/systolic dysfunction, or normal left ventricular diameters/ systolic function with evidence of ventricular scar on contrast enhanced-cardiac magnetic resonance or electroanatomic map. * Sustained monomorphic ventricular tachycardia documented by 12-lead ECG or implantable cardioverter defibrillator (electrograms resistant to antiarrhythmic drug treatment or requiring implantable cardioverter defibrillator therapies. Exclusion Criteria: * • Patients with ventricular arrhythmias attributed to reversible causes.

Locations (1)

AinShams university hospitals

Cairo, Egypt

Outcomes

Primary Outcomes

Number of Participants With Recurrence of Ventricular Tachycardia

Recurrence of ventricular tachycardia implies receiving at least one appropriate implantable cardioverter defibrillator therapy or hospital admission due to symptomatic ventricular tachycardia.

Time frame: 12 months

Secondary Outcomes

Number of Participants Who Experience Cardiac Death

This is defined as unexpected death where a cardiac cause is the most probable etiology

Time frame: 12 months

Number of Participants Who Die From Any Cause (All-cause Mortality)

This includes death from any cause

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.